Results 31 to 40 of about 250,000 (338)

Peroxisome proliferator-activated receptors for hypertension

World Journal of Cardiology, 2014
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor superfamily, which is composed of four members encoded by distinct genes (α, β, γ, and δ). The genes undergo transactivation or transrepression under specific mechanisms that lead to the induction or repression of target gene
Daisuke, Usuda, Tsugiyasu, Kanda
openaire   +2 more sources

The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway

Adipocyte, 2020
The diabetes medication canagliflozin (Cana) is a sodium glucose cotransporter 2 (SGLT2) inhibitor acting by increasing urinary glucose excretion and thus reducing hyperglycaemia. Cana treatment also reduces body weight.
Xuping Yang, Qinhui Liu, Yanping Li, Qin Tang, Tong Wu, Lei Chen, Shiyun Pu, Yingnan Zhao, Guorong Zhang, Cuiyuan Huang, Jinhang Zhang, Zijing Zhang, Ya Huang, Min Zou, Xiongjie Shi, Wei Jiang, Rui Wang, Jinhan He   +17 more
doaj   +1 more source

Peroxisome proliferator-activated receptor alpha plays a crucial role in behavioral repetition and cognitive flexibility in mice [PDF]

, 2015
Acknowledgments We thank Luca Giordano, Giovanni Esposito and Angelo Russo for technical assistance and Dr. Livio Luongo (Second University of Naples–Italy) for critical discussions.
Avagliano, Carmen, Calignano, Antonio, Citraro, Rita, Cristiano, Claudia, D'Agostino, Giuseppe, De Sarro, Giovambattista, Heisler, Lora K, Lyons, David J, Meli, Rosaria, Raso, Giuseppina Mattace, Russo, Emilio, Russo, Roberto   +11 more
core   +2 more sources

Peroxisome Proliferator‐Activated Receptors in Diabetic Nephropathy [PDF]

PPAR Research, 2008
Diabetic nephropathy is a leading cause of end‐stage renal disease, which is increasing in incidence worldwide, despite intensive treatment approaches such as glycemic and blood pressure control in patients with diabetes mellitus. New therapeutic strategies are needed to prevent the onset of diabetic nephropathy.
Shinji Kume, Takashi Uzu, Keiji Isshiki, Daisuke Koya   +3 more
openaire   +3 more sources

Peroxisome Proliferator-Activated Receptors [PDF]

Hypertension, 2003
Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors acting as transcription factors on numerous target genes after heterodimerization with the retinoid X receptor. PPAR-α and PPAR-γ may be activated by different agonists, although the endogenous ligands are unknown.
Ernesto L. Schiffrin, Farhad Amiri, Karim Benkirane, Marc Iglarz, Quy N. Diep   +4 more
openaire   +2 more sources

Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy : pain relief and neuroprotection share a PPAR-alpha-mediated mechanism [PDF]

, 2013
Peer reviewedPublisher ...
Calignano, A, D'Agostino, G, Di Cesare Mannelli, L, Ghelardini, C, Pacini, A, Russo, R, Zanardelli, M   +6 more
core   +4 more sources

Peroxisome Proliferator-Activated Receptor-γ Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids

Frontiers in Immunology, 2018
Although glucocorticoids (GC) represent the most frequently used immunosuppressive drugs, their effects are still not well understood. In our previous studies, we have shown that treatment of monocytes with GC does not cause a global suppression of ...
M. Heming, S. Gran, Saskia-L. Jauch, Lena Fischer-Riepe, A. Russo, L. Klotz, S. Hermann, M. Schäfers, J. Roth, K. Barczyk-Kahlert   +9 more
semanticscholar   +1 more source

The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism [PDF]

, 2019
Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 106) into immune competent ...
Derr-Yellin, Ethel, Ermatov, Nurmukambed, Konger, Raymond L., Ren, Lu, Sahu, Ravi P.   +4 more
core   +1 more source

Peroxisome Proliferator-Activated Receptor-γ in Thyroid Autoimmunity

PPAR Research, 2015
Peroxisome proliferator-activated receptor- (PPAR-) γ expression has been shown in thyroid tissue from patients with thyroiditis or Graves’ disease and furthermore in the orbital tissue of patients with Graves’ ophthalmopathy (GO), such as in extraocular
Silvia Martina Ferrari, Poupak Fallahi, Roberto Vita, Alessandro Antonelli, Salvatore Benvenga   +4 more
doaj   +1 more source

Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases

Cells, 2023
Peroxisome proliferator-activated receptors (PPARs) α, β, and γ are nuclear receptors that orchestrate the transcriptional regulation of genes involved in a variety of biological responses, such as energy metabolism and homeostasis, regulation of ...
In Soo Kim, Prashanta Silwal, Eun-Kyeong Jo   +2 more
doaj   +1 more source